Fund News, Insights & Expert Takes

Targeted cancer therapy uses drugs that interfere with specific molecules cancer cells need to grow and spread, instead of attacking every rapidly dividing cell in the body. Together with immunotherapy and new blood-based tests, it has changed how doctors choose treatment, monitor response and plan follow-up. These advances do not make cancer treatment free of side effects, but they allow therapy to match the biology of each tumor more closely. This article explains how targeted therapy works, what the key clinical trials show, and where the next safety gains are likely to come from.

The silver economy covers the products and services that meet the needs of people aged 50 and over, and in Europe it has grown into one of the largest economic segments on the continent. Population aging is a slow-moving trend, which makes its direction unusually predictable for investors who plan in decades. Central and Eastern Europe is aging faster than most of the European Union, and that speed creates both pressure on health systems and demand for new solutions. This article explains the scale of the silver economy, the demographic data behind it, and why investors treat aging as a long-term investment theme.

Digital pathology is the practice of converting glass slides into high-resolution digital images that pathologists can view, share and analyze on a computer screen. It changes how tissue diagnosis is organized, from the way slides are stored to the way a second opinion reaches a specialist in another city. For a specialty facing rising cancer incidence and a shrinking workforce, it has become one of the most important infrastructure shifts in laboratory medicine. This article explains how digital pathology systems work, what the evidence shows, and why artificial intelligence depends on them.

A brain-computer interface records brain activity and translates it into commands for a computer, a robotic arm or another external device. For people who have lost the ability to move or speak after spinal cord injury, stroke or amyotrophic lateral sclerosis (ALS), that link can restore a channel of communication the body no longer provides. Recent progress in implanted electrodes and machine learning has moved the field from laboratory demonstrations to multi-year clinical trials. This article explains how BCI technology works, where it already helps patients, and which risks and open questions remain.

A biological age test estimates how far the body has aged at the cellular level, independent of the number of years a person has lived. Most tests on the market read DNA methylation patterns, chemical marks on the genome that shift in predictable ways during the aging process. The underlying science is strong across large populations and considerably weaker when one result is used to judge one person's health. This article explains how epigenetic clocks work, what they measure reliably, and where their limits begin.

Most of what keeps an older person independent has nothing to do with hospitals. It is whether the fall gets noticed, whether the medication gets taken, whether the daughter two hundred kilometres away knows that something changed this week. AgeTech is the set of tools built around those ordinary moments, and it has become one of the fastest-moving parts of digital health because the demographic pressure behind it is not going to ease.

Health systems pay for illness after it arrives. National health spending in the United States reached USD 5.3 trillion in 2024, up 7.2% in a single year, and the CMS Office of the Actuary projects USD 9 trillion by 2034, or 20.6% of the economy, in figures published in Health Affairs. Almost none of that money goes to stopping disease before it starts. Preventive health technology exists to change the sequence: measure continuously, detect early, intervene while the problem is still cheap and reversible.

Telemedicine technology is the combination of software, connected medical devices, and telecommunications technology that enables a healthcare provider to diagnose and treat a patient remotely, without an in-person visit. Modern remote care spans live video consultations, home monitoring of vital signs, including blood pressure and blood sugar, and secure record sharing among clinicians. The technology is already capable - the open questions are when virtual care fits, when in-person care is still required, and how health systems pay for it.

Chronic kidney disease (CKD) is a long-term condition in which the kidneys slowly lose their ability to filter waste and extra fluid from the blood. Early detection of kidney disease means finding that damage with an eGFR blood test and a urine ACR test before symptoms appear — the only reliable way to catch it, because the kidneys can lose up to 90% of their function before a person feels unwell. Catching the disease early matters because it lets a care team slow it and prevent kidney failure, while a late diagnosis often leads to dialysis or a transplant.

AI-driven diagnostics is the use of machine learning and computer vision to analyze patient data and detect disease earlier than traditional methods allow. At Aegis Capital, a HealthTech and Longevity VC, we back early-stage startups building these tools across Central and Eastern Europe. Used well, AI systems read medical images, electronic health records, and lab results, then surface patterns and risk factors for a clinician to confirm — working as decision support that improves diagnostic accuracy while physicians keep the final call.

Discover how modern technology transforms everyday information into reliable medical insights — and how, in recent years, the definitions of digital biomarkers have evolved to explain diseases better.

A brief overview of ocular biomarkers and medical innovations, and an assessment of how the diagnosis of neurodegenerative disease is changing.

Investments in medical innovation are rapidly transforming patient care and diagnostic accuracy, and healthcare AI is helping health systems reduce costs while they enhance the quality of care patients receive.

A quick overview of metabolic health and medical technologies — and what you can do to improve your metabolic health while on GLP-1 therapy.

Artificial intelligence transforms modern healthcare by accelerating clinical data analysis, and the goal is to make diagnostic accuracy and access to care both faster and more reliable.

A brief overview of personalized medicine and modern healthcare innovations, and the growing role personalized medicine plays in the prevention, diagnosis, and treatment of disease.

A quick overview of the current landscape and the future of women's health and digital health, and its market potential.

An algorithm can read a standard ECG and identify a weakened left ventricle in a person with no symptoms, a signal no cardiologist can see in the same tracing. Detection at that level has been demonstrated repeatedly since 2019. Survival curves, hospitalization rates and time to treatment have moved far less, and the distance between those two facts defines the current state of the field.

Living longer and living well stopped being the same thing some time ago. A 2024 study in JAMA Network Open covering 183 World Health Organization member states found that the global gap between total years lived and years lived in good health widened from 8.5 years in 2000 to 9.6 years in 2019, and the United States recorded the largest gap of all at 12.4 years. Healthspan is the metric that describes the second number, and longevity medicine exists to close the distance between the two. This article explains what each term measures, what drives the gap, and how it can be shortened.

A prescription that opens on a phone rather than at a pharmacy counter still sounds unusual, yet regulators in the United States and Europe have already cleared software to prevent, manage or treat specific conditions. Digital therapeutics are the part of digital health where a program has to prove clinical effect in trials before it reaches a patient. That evidence requirement separates them from the wellness market, and it also explains why the category grew slowly while consumer health apps multiplied. This article explains what qualifies as a digital therapeutic, how such products are regulated, where the clinical evidence stands, and what still blocks wider adoption.

Epigenetics is the control layer that decides which genes a cell actually uses, and it has become the scientific foundation of the longevity field. Capital is arriving accordingly. Yet for founders, clinicians, and investors working on aging biology in Central and Eastern Europe, the constraint that matters is not scientific at all. It is regulatory, and it sits squarely between a laboratory result and a patient.

Cardiology has become one of the busiest testing grounds for artificial intelligence, with machine-learning tools now reading ECGs, automating echocardiography and flagging disease earlier than the human eye. The real value sits in specific, well-validated tasks — triage, pattern detection and reporting — where AI supports the cardiologist rather than replaces the clinician. Knowing where that value is, where the risks lie, and what it takes to fund and certify these tools is what separates the hype from clinical reality.

Heart disease remains the leading cause of death worldwide, and cardiovascular technology has advanced faster than almost any other area of medicine. Implantable cardiovascular devices now correct a failing rhythm, catheters repair a leaking valve without surgery, and a wearable heart monitor can flag a problem long before a clinic visit. Knowing how these cardiac devices fit together — and what it takes to fund them — explains how heart care is being rebuilt around earlier detection and less invasive treatment.

The spring 2026 edition of the Aegis VC Healthtech Networking Dinner series has officially come to a close. This year, the series took place in an intimate regional format, creating a space for open conversations about healthcare innovation, relationship building, and knowledge exchange among startup founders, investors, industry experts, and ecosystem leaders.

Aegis Capital Invests in SuppMatch – AI-Powered Evidence-Based Supplementation Guidance

A disease of the aging heart that has remained without effective treatment for decades

HealthTech Is Growing Up — And Execution Is Now the Real Test

Early diagnosis of Alzheimer’s disease remains one of medicine’s greatest challenges. Inoko Vision is developing technology that could change this.

Health Tech Forward is an international conference dedicated to innovation in healthcare, bringing together leaders of the healthcare ecosystem, startups, investors, academics, and public sector decision-makers.

For several years, we have been organizing recurring #healthtech networking events that combine hands-on workshops with relationship-building among key industry stakeholders. One such event took place on October 16, 2025, featuring a workshop on expanding to the U.S. market and a panel on due diligence in medical companies, as part of a broader initiative to strengthen collaboration in Poland and internationally.

Aegis Capital has successfully completed the full registration process for its AIFM (ZASI) and ASI, obtaining all required regulatory approvals and becoming fully operational within a secure and transparent structure for its 22 investors. The fund is now focused on building its investment pipeline and preparing its first transactions, with a strategic emphasis on longevity and healthcare.

Anna Badurska has joined Aegis Capital as a Venture Partner, bringing extensive experience in HealthTech and AgeTech innovation and a track record of supporting startups that have raised over €1 billion in funding. She will focus on sourcing high-potential investments and supporting portfolio companies, with a strong emphasis on AI, strategic partnerships, and navigating complex regulatory environments.

Aegis VC raised its fund to PLN 80 million and expanded its investor base to 22 partners. It invests in early-stage tech - mainly healthtech in CEE - with up to PLN 8 million per company.

We’re growing our team. Adrian Maciejewski joins Aegis Capital as Principal, bringing a rare blend of clinical insight and startup experience.

We’re officially live. Backed by new capital and a clear mission, Aegis Capital is here to support the next generation of HealthTech and Longevity founders.